NP001 may lower the levels of activated cytotoxic macrophages in people with ALS, reducing inflammation and further injury to the motor nerves.
NP001 failed to meet endpoints in a phase II clinical trial. But a post hoc analysis suggested evidence of potential benefit in a small subset of people with ALS. We are hopeful that the upcoming phase III trial will be designed and powered in a way that enables assessment of efficacy. However, we continue to urge caution in the reliance on historical controls and post hoc analysis alone to support advancement of any drug through the clinical trial process.
CPMC's Forbes Norris ALS Clinic Director Bob Miller MD talks NP001 and its potential for people with ALS going forward.
Emerging ALS medicines show promise. But key challenges remain to bring them forward to the ALS clinic according to new studies unveiled at ALS MND Chicago.
Methodist Neurological Institute’s Stanley Appel MD talks about the emerging role of cytotoxic microglia in ALS and potential treatment strategies to combat them looking forward.
Topics in the Pipeline